Abstract:Abstract Background 18F-Fluorodeoxyglucose (FDG) PET/CT is emerging as a tool in the diagnosis and evaluation of pulmonary sarcoidosis, however, there is limited consensus regarding its diagnostic performance and prognostic value. Method A meta-analysis was conducted with PubMed, Science Direct, MEDLINE, Scopus, and CENTRAL databases searched up to and including September 2023. 1355 studies were screened, with seventeen ( n = 708 patients) suitable based on their assessment of the diagnostic performance or prognostic value of FDG-PET/CT. Study quality was assessed using the QUADAS-2 tool. Forest plots of pooled sensitivity and specificity were generated to assess diagnostic performance. Pooled changes in SUVmax were correlated with changes in pulmonary function tests (PFT). Results FDG-PET/CT in diagnosing suspected pulmonary sarcoidosis (six studies, n = 400) had a pooled sensitivity of 0.971 (95%CI 0.909–1.000, p = < 0.001) and specificity of 0.873 (95%CI 0.845–0.920)(one study, n = 169). Eleven studies for prognostic analysis ( n = 308) indicated a pooled reduction in pulmonary SUVmax of 4.538 (95%CI 5.653–3.453, p = < 0.001) post-treatment. PFTs displayed improvement post-treatment with a percentage increase in predicted forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) of 7.346% (95%CI 2.257–12.436, p = 0.005) and 3.464% (95%CI -0.205–7.132, p = 0.064), respectively. Reduction in SUVmax correlated significantly with FVC ( r = 0.644, p < 0.001) and DLCO (r = 0.582, p < 0.001) improvement. Conclusion In cases of suspected pulmonary sarcoidosis, FDG-PET/CT demonstrated good diagnostic performance and correlated with functional health scores. FDG-PET/CT may help to guide immunosuppression in cases of complex sarcoidosis or where treatment rationalisation is needed. Clinical relevance statement FDG-PET/CT has demonstrated a high diagnostic performance in the evaluation of suspected pulmonary sarcoidosis with radiologically assessed disease activity correlating strongly with clinically derived pulmonary function tests. Key Points In diagnosing pulmonary sarcoidosis, FDG-PET/CT had a sensitivity and specificity of 0.971 and 0.873, respectively. Disease activity, as determined by SUVmax, reduced following treatment in all the included studies. Reduction in SUVmax correlated with an improvement in functional vital capacity, Diffusion Capacity of the Lungs for Carbon Monoxide, and subjective health scoring systems.

Glucose metabolic rate from four-dimensional [18F]FDG PET/CT to differentiate sarcoid lesions from malignant lesions

Clinical Significance of FDG Single-Photon Emission Computed Tomography: Computed Tomography in the Diagnosis of Head and Neck Cancers and Study of Its Mechanism.

Glucose Metabolic Profile by Visual Assessment Combined with Statistical Parametric Mapping Analysis in Pediatric Patients with Epilepsy.

18F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography in the Diagnosis of Benign Pulmonary Lesions in Sarcoidosis

18F-FDG-PET of Musculoskeletal Tumors: a Correlation with the Expression of Glucose Transporter 1 and Hexokinase II.

Relationship of Ketosis With Myocardial Glucose Uptake Among Patients Undergoing FDG PET/CT for Evaluation of Cardiac Sarcoidosis

Comparison of Cell Proliferation, Protein, and Glucose Metabolism in Musculoskeletal Tumors in a PET Study.

Physiological myocardial 18F-FDG uptake pattern in oncologic PET/CT: comparison with findings in cardiac sarcoidosis

In vivo assessment of safety, biodistribution, and radiation dosimetry of the [18F]Me4FDG PET-radiotracer in adults

FDG PET/CT Imaging of Sarcoidosis.

Brain Metabolic Characteristics Distinguishing Typical and Atypical Benign Epilepsy with Centro-Temporal Spikes.

Evaluation of Clinical Variables Affecting Myocardial Glucose Uptake in Cardiac FDG PET

Functional FDG-PET: Measurement of Task Related Neural Activity in Humans—A Compartment Model Approach and Comparison to fMRI

Methodologic Considerations for Quantitative 18F-FDG PET/CT Studies of Hepatic Glucose Metabolism in Healthy Subjects

Multiparametric Cardiac 18F-FDG PET in Humans: Kinetic Model Selection and Identifiability Analysis

18F-FDG PET Imaging for Differentiating Malignant from Benign Lesions in Patients with Adrenal Masses

A Methodology to Measure Glucose Metabolism by Quantitative Analysis of PET Images

The correlation study between the glucose metabolism of 18F-FDG PET/CT incidental thyroid cancer and clinicopathologic characteristics

Meta-analysis of [18F]FDG-PET/CT in pulmonary sarcoidosis

Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy

AI-enabled CT-guided end-to-end quantification of total cardiac activity in 18FDG cardiac PET/CT for detection of cardiac sarcoidosis